Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

2.

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis.

Colombo F, Durigutto P, De Maso L, Biffi S, Belmonte B, Tripodo C, Oliva R, Bardini P, Marini GM, Terreno E, Pozzato G, Rampazzo E, Bertrand J, Feuerstein B, Javurek J, Havrankova J, Pitzalis C, Nuñez L, Meroni P, Tedesco F, Sblattero D, Macor P.

J Autoimmun. 2019 Jun 15:102288. doi: 10.1016/j.jaut.2019.05.016. [Epub ahead of print]

PMID:
31213399
3.

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.

Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A.

Leukemia. 2019 Aug;33(8):2111-2115. doi: 10.1038/s41375-019-0444-6. Epub 2019 Mar 14. No abstract available.

PMID:
30872781
4.

Usefulness of core needle biopsy for the diagnosis of thyroid Burkitt's lymphoma: a case report and review of the literature.

Bernardi S, Michelli A, Bonazza D, Calabrò V, Zanconati F, Pozzato G, Fabris B.

BMC Endocr Disord. 2018 Nov 19;18(1):86. doi: 10.1186/s12902-018-0312-9. Review.

5.

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.

Mazzaro C, Maso LD, Mauro E, Gattei V, Ghersetti M, Bulian P, Moratelli G, Grassi G, Zorat F, Pozzato G.

Diseases. 2018 May 3;6(2). pii: E35. doi: 10.3390/diseases6020035.

6.

Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.

Farra R, Musiani F, Perrone F, Čemažar M, Kamenšek U, Tonon F, Abrami M, Ručigaj A, Grassi M, Pozzato G, Bonazza D, Zanconati F, Forte G, El Boustani M, Scarabel L, Garziera M, Russo Spena C, De Stefano L, Salis B, Toffoli G, Rizzolio F, Grassi G, Dapas B.

Molecules. 2018 Mar 28;23(4). pii: E777. doi: 10.3390/molecules23040777. Review.

7.

Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.

Mazzaro C, Dal Maso L, Quartuccio L, Ghersetti M, Lenzi M, Mauro E, Bond M, Casarin P, Gattei V, Crosato IM, De Vita S, Pozzato G.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):107-114. Epub 2018 Feb 13.

8.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

9.

In-vitro analysis of Quantum Molecular Resonance effects on human mesenchymal stromal cells.

Sella S, Adami V, Amati E, Bernardi M, Chieregato K, Gatto P, Menarin M, Pozzato A, Pozzato G, Astori G.

PLoS One. 2018 Jan 2;13(1):e0190082. doi: 10.1371/journal.pone.0190082. eCollection 2018.

10.

A transient cutaneous relapse of AML M1 in hematological remission: a case report.

di Meo N, Pozzato G, Leonardo E, Trevisini S, Vichi S, Trevisan G.

Acta Dermatovenerol Alp Pannonica Adriat. 2017 Dec;26(4):109-111.

11.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
12.

Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines.

Stacul F, Bertolotto M, Thomsen HS, Pozzato G, Ugolini D, Bellin MF, Bongartz G, Clement O, Heinz-Peer G, van der Molen A, Reimer P, Webb JAW; ESUR Contrast Media Safety Committee.

Eur Radiol. 2018 Feb;28(2):683-691. doi: 10.1007/s00330-017-5023-5. Epub 2017 Aug 30. Review.

13.

Potential Applications of Nanocellulose-Containing Materials in the Biomedical Field.

Halib N, Perrone F, Cemazar M, Dapas B, Farra R, Abrami M, Chiarappa G, Forte G, Zanconati F, Pozzato G, Murena L, Fiotti N, Lapasin R, Cansolino L, Grassi G, Grassi M.

Materials (Basel). 2017 Aug 21;10(8). pii: E977. doi: 10.3390/ma10080977. Review.

14.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

15.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
16.

Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.

Pozzato G, Mazzaro C, Gattei V.

Clin Liver Dis. 2017 Aug;21(3):499-515. doi: 10.1016/j.cld.2017.03.006. Epub 2017 May 18. Review.

PMID:
28689589
17.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

18.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

19.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
20.

Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.

Scarabel L, Perrone F, Garziera M, Farra R, Grassi M, Musiani F, Russo Spena C, Salis B, De Stefano L, Toffoli G, Rizzolio F, Tonon F, Abrami M, Chiarappa G, Pozzato G, Forte G, Grassi G, Dapas B.

Expert Opin Drug Deliv. 2017 Jun;14(6):797-810. doi: 10.1080/17425247.2017.1292247. Epub 2017 Feb 17. Review.

PMID:
28266887
21.

Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs.

Farra R, Scaggiante B, Guerra C, Pozzato G, Grassi M, Zanconati F, Perrone F, Ferrari C, Trotta F, Grassi G, Dapas B.

Int J Pharm. 2017 Jun 20;525(2):367-376. doi: 10.1016/j.ijpharm.2017.02.031. Epub 2017 Feb 14.

PMID:
28229942
22.

Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells.

Cavallaro G, Farra R, Craparo EF, Sardo C, Porsio B, Giammona G, Perrone F, Grassi M, Pozzato G, Grassi G, Dapas B.

Int J Pharm. 2017 Jun 20;525(2):397-406. doi: 10.1016/j.ijpharm.2017.01.034. Epub 2017 Jan 21.

PMID:
28119125
23.

HLA-G regulatory polymorphisms are associated with susceptibility to HCV infection.

Catamo E, Zupin L, Freato N, Polesello V, Celsi F, Crocè SL, Masutti F, Pozzato G, Segat L, Crovella S.

HLA. 2017 Mar;89(3):135-142. doi: 10.1111/tan.12959. Epub 2017 Jan 13.

PMID:
28083985
24.

DEFB1 polymorphisms and salivary hBD-1 concentration in Oral Lichen Planus patients and healthy subjects.

Polesello V, Zupin L, Di Lenarda R, Biasotto M, Pozzato G, Ottaviani G, Gobbo M, Crovella S, Segat L.

Arch Oral Biol. 2017 Jan;73:161-165. doi: 10.1016/j.archoralbio.2016.10.008. Epub 2016 Oct 12.

PMID:
27770642
25.

CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response.

Zupin L, Polesello V, Alberi G, Moratelli G, Crocè SL, Masutti F, Pozzato G, Crovella S, Segat L.

Mol Immunol. 2016 Aug;76:49-54. doi: 10.1016/j.molimm.2016.06.009. Epub 2016 Jun 24.

PMID:
27348632
26.

MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response.

Zupin L, Polesello V, Alberi G, Moratelli G, Crocè SL, Masutti F, Pozzato G, Crovella S, Segat L.

Scand J Immunol. 2016 Jul;84(1):61-9. doi: 10.1111/sji.12444.

27.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
28.

The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma.

Farra R, Grassi G, Tonon F, Abrami M, Grassi M, Pozzato G, Fiotti N, Forte G, Dapas B.

Curr Drug Deliv. 2017;14(2):272-281. doi: 10.2174/1567201813666160527141742. Review.

PMID:
27109336
29.

Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC.

Mazzaro C, Dal Maso L, Urraro T, Mauro E, Castelnovo L, Casarin P, Monti G, Gattei V, Zignego AL, Pozzato G.

Dig Liver Dis. 2016 Jul;48(7):780-4. doi: 10.1016/j.dld.2016.03.018. Epub 2016 Apr 2.

PMID:
27106525
30.

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.

Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, Efremov DG.

Blood. 2016 Jun 23;127(25):3192-201. doi: 10.1182/blood-2015-10-675009. Epub 2016 Apr 19.

31.

Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.

Scaggiante B, Farra R, Dapas B, Baj G, Pozzato G, Grassi M, Zanconati F, Grassi G.

Int J Pharm. 2016 Jun 15;506(1-2):268-79. doi: 10.1016/j.ijpharm.2016.04.031. Epub 2016 Apr 16.

PMID:
27094354
32.

Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, Bulian P, Serraino D, Gattei V.

World J Hepatol. 2016 Jan 18;8(2):107-16. doi: 10.4254/wjh.v8.i2.107. Review.

33.

Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs.

Barba AA, Lamberti G, Sardo C, Dapas B, Abrami M, Grassi M, Farra R, Tonon F, Forte G, Musiani F, Licciardi M, Pozzato G, Zanconati F, Scaggiante B, Grassi G, Cavallaro G.

Curr Drug Metab. 2015;16(6):427-52. Review.

PMID:
26264345
34.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
35.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
36.

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.

Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, Pozzato G, Núñez L, Tripodo C, Macor P, Biffi S.

Int J Nanomedicine. 2015 Jun 22;10:4099-109. doi: 10.2147/IJN.S78995. eCollection 2015.

37.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R.

Oncotarget. 2015 Aug 7;6(22):19102-17.

38.

Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration.

Polesello V, Zupin L, Di Lenarda R, Biasotto M, Ottaviani G, Gobbo M, Cecco L, Alberi G, Pozzato G, Crovella S, Segat L.

Arch Oral Biol. 2015 Jul;60(7):1054-8. doi: 10.1016/j.archoralbio.2015.03.009. Epub 2015 Mar 28.

PMID:
25939140
39.

Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.

Mazzaro C, Panarello G, Mauro E, Gattei V, Pozzato G.

Dig Liver Dis. 2015 Jul;47(7):613-6. doi: 10.1016/j.dld.2015.03.020. Epub 2015 Mar 31.

PMID:
25890508
40.

Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.

Farra R, Dapas B, Baiz D, Tonon F, Chiaretti S, Del Sal G, Rustighi A, Elvassore N, Pozzato G, Grassi M, Grassi G.

Biochimie. 2015 May;112:85-95. doi: 10.1016/j.biochi.2015.02.015. Epub 2015 Mar 3.

PMID:
25742740
41.

Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F, Grassi G.

World J Gastroenterol. 2014 Feb 7;20(5):1268-88. doi: 10.3748/wjg.v20.i5.1268. Review.

42.

Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.

Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G.

World J Gastroenterol. 2014 Jan 21;20(3):795-803. doi: 10.3748/wjg.v20.i3.795.

43.

No evidence of Polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV.

Comar M, Zanotta N, Del Savio R, Vascotto F, Calabrese N, Zorat F, Pozzato G.

J Med Virol. 2014 Apr;86(4):666-71. doi: 10.1002/jmv.23867. Epub 2013 Dec 30.

PMID:
24374940
44.

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo À R, Guarini A, Gattei V.

J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.

45.

New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.

Mezzaroba N, Zorzet S, Secco E, Biffi S, Tripodo C, Calvaruso M, Mendoza-Maldonado R, Capolla S, Granzotto M, Spretz R, Larsen G, Noriega S, Lucafò M, Mansilla E, Garrovo C, Marín GH, Baj G, Gattei V, Pozzato G, Núñez L, Macor P.

PLoS One. 2013 Sep 30;8(9):e74216. doi: 10.1371/journal.pone.0074216. eCollection 2013.

46.

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V.

Blood. 2013 Nov 7;122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

47.

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V.

Leuk Lymphoma. 2014 Apr;55(4):841-7. doi: 10.3109/10428194.2013.803223. Epub 2013 Oct 17.

PMID:
23829282
48.

Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors.

Scaggiante B, Dapas B, Farra R, Grassi M, Pozzato G, Giansante C, Fiotti N, Tamai E, Tonon F, Grassi G.

Curr Drug Metab. 2013 Jun;14(5):565-82. Review.

PMID:
23687927
49.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1.

50.

ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells.

Dal Bo M, Pozzo F, Bomben R, Degan M, Marconi D, Zucchetto A, Rossi D, Pozzato G, Zauli G, Gaidano G, Del Poeta G, Gattei V.

Br J Haematol. 2013 May;161(4):596-9. doi: 10.1111/bjh.12258. Epub 2013 Feb 14. No abstract available.

PMID:
23406297

Supplemental Content

Loading ...
Support Center